Moderna Shares Double on Success of mRNA Cancer Vaccine
Moderna shares have surged nearly 600% this year amid high expectations for its experimental melanoma vaccine, intismeran autogene, co-developed with Merck. Five-year results demonstrate a 49% reduction in disease progression or death. While investors rally around the personalized mRNA treatment, the broader market awaits the complete data release in Madrid. Meanwhile, Nasdaq announced that Moderna will join the Nasdaq-100 index before the opening bell on October 9, replacing Warner Bros. Discovery.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Moderna stock has surged nearly 600% this year on cancer vaccine trial results.
- ✓ Five-year results with the Moderna and MSD melanoma jab show a 49% reduction in disease progression or death.
- ✓ Nasdaq announced on October 1 that Moderna will join the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery.
What changed
Moderna shares climbed ahead of an upcoming full data readout in Madrid and the company's scheduled inclusion in the Nasdaq-100 index.
Live updates
-
Moderna Shares Climb on Melanoma Vaccine Data Ahead of Nasdaq Return
Moderna shares have surged nearly 600% this year amid high expectations for its experimental melanoma vaccine, intismeran autogene, co-developed with Merck. Five-year results demonstrate a 49% reduction in disease progression or death. While investors rally around the personalized mRNA treatment, the broader market awaits the complete data release in Madrid. Meanwhile, Nasdaq announced that Moderna will join the Nasdaq-100 index before the opening bell on October 9, replacing Warner Bros. Discovery.
Why it matters
The surge in valuation follows positive Phase 3 results from the INTerpath-001 trial, which met primary endpoints for recurrence-free survival and distant metastasis-free survival when combined with Merck's Keytruda. Financial institutions have urged caution despite the clinical milestones, with Citi previously downgrading the stock due to extreme market expectations.
What is confirmed
- Moderna stock has surged nearly 600% this year on cancer vaccine trial results.
- Five-year results with the Moderna and MSD melanoma jab show a 49% reduction in disease progression or death.
- Nasdaq announced on October 1 that Moderna will join the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery.
Still unconfirmed
- The complete trial data will be fully evaluated by the market following its presentation in Madrid.
What to watch next
- The full data readout scheduled to be presented in Madrid.
- Moderna's official entry into the Nasdaq-100 index on October 9.
confidence 90%Sources used for this update (5)
- pharmaphorum.com — Data builds behind Moderna's skin cancer vaccine
- 247wallst.com — Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
- finance.yahoo.com — MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail ...
- www.gurufocus.com — Moderna (MRNA) Shares Surge on Cancer Vaccine Optimism ...
- www.biopharmadive.com — Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug | BioPharma Dive
-
Moderna Cancer Vaccine Trial Success Triggers Massive Surge and Citi Downgrade
Moderna shares have surged following positive Phase 3 results for intismeran autogene, an individualized neoantigen therapy combined with Merck's Keytruda in melanoma patients. The INTerpath-001 trial met its primary endpoints for recurrence-free survival and distant metastasis-free survival. While cancer experts praise the personalized mRNA approach, financial institutions warn that the soaring valuation has reached unsustainable levels. Citi downgraded the stock to sell with an $80 price target, citing extreme market expectations that leave little room for error despite the milestone clinical data.
Why it matters
The successful trial results validate personalized mRNA oncology after years of historical setbacks in the field. Merck exercised an option to collaborate on the personalized RNA-based cancer vaccine through a $250 million payment, cementing a partnership that began in 2016. Analysts highlight that manufacturing complexity, high costs, and reimbursement hurdles still pose commercial challenges for the platform.
What is confirmed
- Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene combined with Keytruda.
- The Phase 3 trial met endpoints of recurrence-free survival and distant metastasis-free survival in the adjuvant melanoma setting.
- Citi analyst Geoff Meacham downgraded Moderna to sell while raising the price target to $80.
- Merck previously paid $250 million to take up an option on the personalized RNA-based cancer vaccine.
Still unconfirmed
- Laidlaw analyst Yale Jen flagged possible data releases in other cancers starting from 2027.
- Moderna has engaged in talks with Middle East partners regarding potential investment and manufacturing cooperation.
What to watch next
- Upcoming presentations of detailed efficacy and manufacturing data at international medical meetings
- Regulatory submissions by Merck and Moderna for intismeran autogene in combination with Keytruda
confidence 100%Sources used for this update (20)
- madison.com — Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
- 247wallst.com — Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
- www.merck.com — Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoin....
- stocktwits.com — Nasdaq, S&P 500 Futures Fall As Oil Spikes On Trump’s Snub To Iran: MU, NVDA, SKHY, SPCX, NIO Stocks In....
- www.biopharmadive.com — Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data | BioPharma Dive
- bullishdaily.com — Moderna–Merck Melanoma Vaccine Success Reframes the ...
- finance.yahoo.com — Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success ...
- pharmaphorum.com — Merck gets on board with Moderna cancer vaccine in $250m deal
- www.marketbeat.com — Morgan Stanley (MS) Stock Price, News & Analysis
- www.nature.com — RNA therapeutics: current status and future directions | Signal Transduction and Targeted Therapy
- stocktwits.com — MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Can....
- pharmaphorum.com — MSD, Moderna start phase 3 trial of mRNA cancer jab
-
Moderna Shares Rise After Phase 3 Melanoma Data Earns Symposium Slot
Moderna shares rose 9% after the company secured a Presidential Symposium slot at Europe's leading oncology congress to present Phase 3 melanoma vaccine data. This price jump follows a monthly surge of 137% driven by the company's mRNA cancer pipeline. While the specific dataset remains unseen, the prestige of the presentation slot is driving market optimism. The company continues to manage high cash burn and competition from rivals like Amgen while operating in a cancer vaccine market projected to grow at a CAGR of 36% from 2026 to 2036.
Why it matters
Moderna is pivoting its mRNA technology from infectious diseases to oncology. The company previously saw stock gains between 7.1% and 9.37% following a presentation at the Morgan Stanley Global Healthcare Conference.
What is confirmed
- Moderna shares increased 9% following the announcement of a Presidential Symposium slot at Europe's top oncology congress.
- The cancer vaccines market is projected to grow at a CAGR of 36% between 2026 and 2036.
Still unconfirmed
- The scheduling of the symposium slot signals positive results for the unseen Phase 3 melanoma dataset.
What to watch next
- Release of the actual Phase 3 melanoma dataset at the oncology congress.
- Updated cash burn figures and financial reports from Moderna.
confidence 90%Sources used for this update (2)
- 247wallst.com — Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
- finance.yahoo.com — Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036) | DelveInsight
-
Moderna Shares Rise Following Cancer Vaccine Trial Results and Conference
Moderna stock climbed between 7.1% and 9.37% on Thursday following the release of promising late-stage vaccine trial results and a presentation at the Morgan Stanley Global Healthcare Conference. These gains follow a monthly surge of 137% as investors react to the company's mRNA cancer vaccine pipeline. While the stock continues to climb, the company still faces high cash burn and competition from firms like Amgen.
Why it matters
The company's valuation has nearly tripled in one month. This growth reflects a shift in investor sentiment regarding the viability of mRNA technology for oncology.
Still unconfirmed
- Moderna stocks traded up 9.37 percent following promising late-stage vaccine trial results.
- Shares jumped 7.1 percent after a presentation at the Morgan Stanley Global Healthcare Conference.
What to watch next
- Publication of the full late-stage trial data
- Updated analyst valuations following the Morgan Stanley conference
confidence 70%Sources used for this update (2)
- www.timothysykes.com — MRNA Stock Rockets As Cancer Breakthrough Redefines The Story
- finance.yahoo.com — Why Are Moderna (MRNA) Shares Soaring Today
-
Moderna Shares Rise 6% as Monthly Gains Reach 137%
Moderna stock increased 6% on Thursday, extending a monthly surge of 137% driven by the trade surrounding its mRNA cancer vaccine. The company's valuation has nearly tripled in one month. This growth occurs despite a lack of new trial results or analyst upgrades to justify the recent climb. BioNTech and Novavax shares also saw modest increases. Investors are weighing these gains against Moderna's continued cash burn and the valuation of competitors like Amgen.
Why it matters
Moderna is attempting to leverage its high share price to fund an expanded oncology pipeline. This strategy faces scrutiny from firms like Rothschild and Co., which downgraded the stock to sell. Analysts are comparing Moderna's spending patterns to revenue-generating peers in the biotech sector.
What is confirmed
- Moderna shares rose 6% on Thursday.
- Moderna shares have increased 137% over the past month.
- BioNTech and Novavax shares moved higher.
Still unconfirmed
- Moderna's stock has nearly tripled in a single month without new trial results or analyst upgrades.
What to watch next
- Release of new clinical trial results for the mRNA cancer vaccine
- Further valuation adjustments from Rothschild and Co.
- Revenue reports comparing Moderna's cash burn to Amgen's earnings
confidence 90%Sources used for this update (3)
- jen.jiji.com — Sustainability: Institutions and businesses in Naples discuss sustainable transition (2)
- jen.jiji.com — New malaria alert in Germany, one dead and one infected: both live near Frankfurt airport
- finance.yahoo.com — Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
-
Moderna Valuation Faces Scrutiny Amid Oncology Success
Moderna shares have doubled following the clinical success of its mRNA cancer vaccine, though the company continues to burn cash. This price surge led Rothschild and Co. to downgrade the stock from neutral to sell, citing an overvalued position. While Moderna seeks to use its high share price to fund a broader oncology pipeline, analysts are monitoring the competition between Moderna and BioNTech. Market comparisons now contrast Moderna's valuation with Amgen, which generates billions in revenue compared to Moderna's current spending patterns.
Why it matters
The oncology vaccine sector is a primary growth area for mRNA technology. Moderna's ability to secure funding for its pipeline depends on maintaining investor confidence despite high spending.
What is confirmed
- Rothschild and Co. downgraded Moderna stock from neutral to sell.
- Moderna shares doubled due to the success of its mRNA cancer vaccine.
Still unconfirmed
- Amgen trades at a fraction of Moderna's valuation.
- Moderna is burning cash while Amgen generates billions.
What to watch next
- Financial reports detailing Moderna's cash burn rate
- Clinical trial updates for the oncology pipeline
- Market share shifts between Moderna and BioNTech
confidence 80%Sources used for this update (14)
- jen.jiji.com — 'When I see you again' is Gino Paoli's last unreleased song, the missed duet with Ornella Vanoni
- jen.jiji.com — Short-term rentals: open clash between EU, homeowners and tourist platforms
- jen.jiji.com — Juve, Locatelli underwent knee surgery: here's when he'll return to the field
- jen.jiji.com — Fabregas snubs Champions League debut: "It's just another game"
- jen.jiji.com — 'Red Bull 64 Bars Live', Ele A, Nerissima Serpe and Papa V as special guests: the live in Taranto
- jen.jiji.com — Vuelta a España, today 18th stage: time, route and where to watch it
- jen.jiji.com — Kefir superfood or current trend? Bassetti: "Here's what science really says"
- www.fool.com — Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
- jen.jiji.com — Agrigento, illegal house inherited from father: Deputy Mayor Crosta resigns
- jen.jiji.com — Weather, goodbye mugginess with the Azores High: but from Tuesday everything changes, rain arriving
- jen.jiji.com — Ostia, construction worker dies falling from crane basket. The other clings to the balcony: "Saved by the residents"
- jen.jiji.com — Food, Anir Confindustria: "For large-scale catering, more certainty on contracts and rules"
-
Moderna Shares Double Following Success of mRNA Cancer Vaccine
Rothschild and Co. has downgraded Moderna stock from neutral to sell because the firm considers the company overvalued. This valuation shift follows a price surge driven by the clinical success of Moderna's mRNA cancer vaccine. Wall Street analysts remain closely focused on the market competition between Moderna and BioNTech within the oncology vaccine sector. Moderna has attempted to leverage its elevated share prices to secure financial support for its broader oncology pipeline development, prompting the recent downgrade from the research firm.
Why it matters
Personalized mRNA cancer vaccines represent a developing frontier in oncology, drawing intense market interest and driving major stock fluctuations. Financial institutions are closely monitoring how biotech firms fund their clinical pipelines amid shifting valuations. Competition between major players like Moderna and BioNTech continues to dictate market sentiment.
What is confirmed
- Rothschild and Co. downgraded Moderna stock to sell from neutral, stating the company is now overvalued.
- The valuation shift follows a surge in share prices driven by the success of Moderna's mRNA cancer vaccine.
What to watch next
- Further clinical trial results for mRNA cancer vaccines
- Developments in the market competition between Moderna and BioNTech
- Moderna's ongoing efforts to fund its oncology pipeline
confidence 100%Sources used for this update (5)
- jen.jiji.com — Food: Barilla, with La tavolata reunites paddock family on the starting grid of Monza (2)
- jen.jiji.com — No more toilet paper, the 'smart toilet' arrives: what it is and how it works
- www.stl.news — Five Best-Performing Stocks of 2026 So Far
- www.usatoday.com — Personalized mRNA cancer vaccines offer new hope. We explain
- jen.jiji.com — AfD soars in Saxony-Anhalt, Vannacci: "Merz has an ulcer, let no one sleep"
-
Rothschild & Co. Downgrades Moderna to Sell Following Stock Surge
Rothschild & Co. has downgraded Moderna stock to sell from neutral, stating the company is now overvalued. This shift follows a surge in share prices driven by the success of Moderna's mRNA cancer vaccine. While Wall Street remains focused on the competition between Moderna and BioNTech in the cancer vaccine market, the research firm believes the current valuation exceeds the company's worth. This follows Moderna's recent efforts to capitalize on high share prices to fund its oncology pipeline.
Why it matters
Moderna developed a personalized neoantigen vaccine, intismeran autogene, with Merck that reduced melanoma recurrence risk by roughly half in a Phase 3 trial of 1,137 patients. To fund these initiatives, the company raised 2.6 billion dollars through an upsized convertible note offering.
What is confirmed
- Rothschild & Co. downgraded Moderna stock to sell from neutral.
- Rothschild & Co. stated Moderna is now overvalued after a stock surge led by its cancer vaccine.
What to watch next
- Further analyst rating changes from other major research firms
- Clinical updates or regulatory filings for intismeran autogene
- Financial reports detailing the deployment of the 2.6 billion dollar capital raise
confidence 100%Sources used for this update (8)
- jen.jiji.com — Tamberi and Bontempi, the fairytale party for their daughter Camilla's first birthday
- jen.jiji.com — Serie A, today Atalanta-Bologna: time, probable lineups and where to watch it on TV
- jen.jiji.com — USA, Bank of America Vice President is the woman stabbed to death in Times Square
- jen.jiji.com — US Open, Musetti and Bellucci in the second round
- finance.yahoo.com — Is BioNTech Stock a No-Brainer Buy on the Dip?
- jen.jiji.com — Vuelta a España, today twelfth stage: schedule, route and where to watch it
- www.cnbc.com — Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. says
- www.fool.com — BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
-
Moderna Upsizes Funding to $2.6 Billion Following Cancer Vaccine Success
Moderna has raised $2.6 billion through an upsized convertible note offering to fund its cancer vaccine initiatives. This financial move follows a Phase 3 trial of 1,137 patients where the personalized neoantigen vaccine intismeran autogene, developed with Merck, reduced melanoma recurrence risk by roughly half. The company is leveraging a multi-year high in share prices to secure this capital. Separately, the FDA has cleared updated COVID vaccines.
Why it matters
The funding supports the scale-up of mRNA technology for oncology. The intismeran autogene trial represents a significant shift from infectious disease to personalized cancer treatment.
What is confirmed
- Moderna raised $2.6 billion to support its cancer research.
- The FDA cleared updated COVID vaccines.
- Intismeran autogene reduced melanoma recurrence risk by roughly half in a Phase 3 trial of 1,137 patients.
What to watch next
- Updates on the commercial rollout of intismeran autogene
- Further FDA approvals for mRNA cancer therapies
confidence 100%Sources used for this update (6)
- jen.jiji.com — Girl dies of diphtheria in Palermo: autopsy underway
- www.newscase.com — BioNTech’s Sympathy Surge Masks a Structural Squeeze
- jen.jiji.com — Coffee at the bar, Stoppani (Fipe): "2 euro cup a remote hypothesis, but pay attention to energy and inflation"
- finance.yahoo.com — Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
- jen.jiji.com — 16-year-old who had left home found lifeless in the Po river
- jen.jiji.com — Udine, woman stabbed to death: husband arrested
-
Moderna Raises $2 Billion Following Cancer Vaccine Success
Moderna is raising $2 billion through convertible notes due 2032 to capitalize on its recent stock surge. The company has an option to secure an additional $300 million. This financial move follows the announcement that Moderna and Merck's personalized neoantigen vaccine, intismeran autogene, reduced melanoma recurrence risk by roughly half in a Phase 3 trial of 1,137 patients. While shares hit a multi-year high, the company is now leveraging that valuation to secure funding for its cancer vaccine initiatives.
Why it matters
The funding follows a period of high volatility where shares peaked and then dipped 5.13% on August 24 due to profit-taking. Moderna's partnership with Merck represents a significant shift toward mRNA cancer therapies. This development occurs as competitors like BioNTech face financial losses and restructuring.
What is confirmed
- Moderna is selling convertible notes due 2032 to raise $2 billion.
- Moderna has an option to raise an additional $300 million.
- A Phase 3 trial of 1,137 patients showed the intismeran autogene vaccine reduced melanoma recurrence risk by roughly half.
- Moderna shares fell 5.13% on August 24.
What to watch next
- Analysts' updates to price targets following the $2 billion capital raise
- Regulatory approval timelines for intismeran autogene
confidence 100%Sources used for this update (9)
- en.protothema.gr — What K.M. & Tsipras say about the elections, the phantom investor and the crème de la crème, bonuses at Astieras & shipowners selling tankers
- jen.jiji.com — European Volleyball Championship, Italy-France 3-1: Azzurre to the round of 16 as group winners
- finance.yahoo.com — Moderna raises $2 billion in convertible notes for cancer vaccine
- jen.jiji.com — Atalanta beats Hapoel 1-0 and qualifies for the Conference League
- jen.jiji.com — Heat, how to face tropical nights: the four (fundamental) tips from the expert
- jen.jiji.com — Ranucci, Esperia: "In the book he says Gabanelli called him while he was saving a man, but a video with another version emerges"
- jen.jiji.com — Ukraine, Russian raids on 'Nova Post' warehouses in Kyiv region
- uk.finance.yahoo.com — Merck (MRK) Stock Looks Fully Priced After A 127% Run
- www.ad-hoc-news.de — BioNTech's Balancing Act: A New CEO, a Costly Pivot, and a Pipeline That Must Prove Itself
-
Moderna mRNA Cancer Vaccine Halves Melanoma Recurrence in Phase 3 Trial
Moderna and Merck announced on August 19 that their personalized neoantigen vaccine, intismeran autogene, reduced the risk of melanoma recurrence by roughly half. The Phase 3 trial included 1,137 patients. While the stock surged following the results, Moderna shares fell 5.13% on August 24 as investors engaged in profit-taking and valuation resets. Analysts continue to maintain cautious price targets that remain well below the stock's temporary peak.
Why it matters
This trial represents the first personalized neoantigen vaccine to clear Phase 3. The partnership between Moderna and Merck aims to prevent skin cancer from returning after initial treatment.
What is confirmed
- Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine.
- The vaccine, intismeran autogene, cut melanoma recurrence risk by roughly half in 1,137 patients.
- Moderna shares moved down by 5.13% on August 24.
What to watch next
- Regulatory filing dates for intismeran autogene
- Updated analyst price targets following the valuation reset
confidence 90%Sources used for this update (4)
- en.protothema.gr — Mitsotakis’s order to “round up the ripe ones living off public money,” the Thessaloniki Fair, Tsipras and Samaras, the Spetses tip-offs, and is George Papandreou’s son ...
- consent.yahoo.com — Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax
- www.tradingkey.com — Moderna Inc Stock (MRNA) Moved Down by 5.13% on Aug 24: A Full Analysis
- www.techtimes.com — Personalized mRNA Cancer Vaccine Clears Phase 3: Melanoma Recurrence Cut by Half
-
Moderna Shares Double on mRNA Cancer Vaccine Success
Moderna's shares have more than doubled following promising results from its mRNA cancer vaccine, developed in collaboration with Merck, in a late-stage melanoma trial. The vaccine shows potential in preventing skin cancer recurrence. The trial involved over 1,000 patients and demonstrated a significant reduction in cancer recurrence.
Why it matters
The success of Moderna's mRNA cancer vaccine could pave the way for a new wave of cancer treatments. The vaccine uses a personalized neoantigen therapy approach, which involves tailoring the treatment to individual patients. This breakthrough has significant implications for the future of cancer treatment and could lead to the development of similar vaccines for other types of cancer.
What is confirmed
- Moderna's mRNA cancer vaccine helped prevent the return and spread of melanoma in a trial involving more than 1,000 patients.
- Moderna's shares have more than doubled on the success of its mRNA cancer vaccine.
- BioNTech shares jumped 24% on Moderna's cancer vaccine success, highlighting mRNA platform potential.
- The vaccine's success could usher in a wave of cancer vaccines.
Still unconfirmed
- It is unclear if the vaccine's success will be a one-off or open a portal to a new way of treating cancers in general.
What to watch next
- Further trial results and FDA approval
- Development of similar vaccines for other types of cancer
- Impact on Moderna's and Merck's stock prices
confidence 85%Sources used for this update (5)
- www.livemint.com — It now seems possible to vaccinate against cancer
- omaha.com — Moderna, Merck breakthrough could usher in cancer vaccines
- www.ad-hoc-news.de — BioNTech's Sympathy Surge: When a Rival's Data Becomes Your Stock's Best Friend
- www.genengnews.com — StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too
- www.theglobeandmail.com — Why Tempus AI Skyrocketed This Week
-
Moderna Shares Double on mRNA Cancer Vaccine Success
Moderna's shares have doubled amid promising results from its mRNA cancer vaccine, developed in collaboration with Merck, in a late-stage melanoma trial. The vaccine shows potential in preventing skin cancer recurrence. Moderna's shares have seen significant fluctuations, rising 8% on Friday.
Why it matters
The success of Moderna's mRNA cancer vaccine marks a significant moment in cancer treatment, offering new hope for patients. The vaccine is a personalized treatment that may help prevent skin cancer from recurring. This development has substantial implications for the future of cancer therapy.
What is confirmed
- Moderna's shares have doubled on the success of its mRNA cancer vaccine
- The mRNA cancer vaccine shows promise in preventing skin cancer recurrence
- Moderna's shares have seen significant fluctuations, rising 8% on Friday
What to watch next
- Further trial results for the mRNA cancer vaccine
- Regulatory decisions on the vaccine's approval
- Long-term efficacy and safety data for the vaccine
confidence 85%Sources used for this update (6)
- baynews9.com — New study shows personalized vaccine may help prevent skin cancer from recurring in patients
- 247wallst.com — Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session
- www.aol.com — Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead
- en.sedaily.com — SK hynix to Buy Back, Cancel 40 Trillion Won in Shares; KOSPI Retakes 6,800
- en.sedaily.com — Korea to Build 2 More Chip Fabs in Honam, Adding to 6-Plus Plan by 2040
- www.cheddar.com — Big Business This Week: Bond Market Turmoil and The Broader Economy
-
Moderna Shares Double on mRNA Cancer Vaccine Success
Moderna and Merck's mRNA cancer vaccine showed promise in a late-stage melanoma trial, with Moderna's shares soaring 90%. The vaccine, a collaboration between the two companies, has doubled Moderna's shares. This development could mark a significant moment in cancer treatment.
Why it matters
The mRNA cancer vaccine is a collaboration between Moderna and Merck, two major pharmaceutical companies. The vaccine's success in a late-stage trial could pave the way for a new approach to cancer treatment. Moderna's stock has seen significant gains following the announcement. The companies' work on mRNA technology has been closely watched by the medical community.
What is confirmed
- Moderna and Merck's mRNA cancer vaccine succeeded in a late-stage melanoma trial.
- Moderna's shares soared 90% following the announcement.
What to watch next
- Further details on the trial results
- Regulatory approval process for the vaccine
- Potential impact on cancer treatment options
confidence 100%Sources used for this update (5)
- STAT — Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
- CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
- The Washington Post — Cancer treatment could face landmark moment with promising vaccine
- WSJ — Moderna Shares Double on Success of mRNA Cancer Vaccine
- Bloomberg.com — Watch Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community